Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 76 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pramipexole Clear all
Completed Phase 4 Interventional

A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

NCT00375284
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Pramipexole
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
52
States / cities
Birmingham, Alabama • Dothan, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 16, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Pramipexole as a Treatment for Cocaine Dependence

NCT01651377
View directory record Official record
Conditions
Cocaine Addiction, Cocaine Abuse, Cocaine Dependence, Substance Abuse
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Oct 16, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease

NCT00666653
View directory record Official record
Conditions
Parkinson's Disease
Interventions
pramipexole
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 25, 2008 · Synced Oct 16, 2026, 5:05 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

NCT05748600
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack
Interventions
Dexpramipexole Dihydrochloride, Placebo
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
12 Years to 99 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
146
States / cities
Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 16, 2026, 5:05 PM EDT
Completed Phase 1Phase 2 Interventional

Pramipexole and Morphine for Renal Colic

NCT04160520
View directory record Official record
Conditions
Renal Colic
Interventions
Pramipexole, Morphine, Placebo oral tablet
Drug
Lead sponsor
East Carolina University
Other
Eligibility
19 Years to 66 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 16, 2026, 5:05 PM EDT
Completed Phase 3 Interventional

A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease

NCT00242008
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Timeline
2004 – 2005
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 16, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Dexpramipexole in ALS

NCT01281189
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Placebo
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
43
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 16, 2026, 5:05 PM EDT
Not listed Phase 2 Interventional

A Study in Patients With Major Depressive Disorder

NCT03642964
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
CTC-501
Drug
Lead sponsor
Chase Therapeutics Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 16, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)

NCT01536249
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Cimetidine plus Dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 16, 2026, 5:05 PM EDT
Terminated No phase listed Observational

The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)

NCT00804479
View directory record Official record
Conditions
Parkinson's Disease
Interventions
No intervention.
Other
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 16, 2026, 5:05 PM EDT
Withdrawn Phase 4 Interventional

Butrans for Treatment of Restless Legs Syndrome

NCT02138357
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
buprenorphine transdermal delivery system (BTDS), Placebo for BTDS patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 16, 2026, 5:05 PM EDT
Completed Phase 1Phase 2 Interventional

R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis

NCT00140218
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
R(+) pramipexole dihydrochloride monohydrate
Drug
Lead sponsor
Bennett, James P., Jr., M.D., Ph.D.
Individual
Eligibility
21 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2008 · Synced Oct 16, 2026, 5:05 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD

NCT04759703
View directory record Official record
Conditions
Sleep Disorder, Restless Legs Syndrome, Opioid-use Disorder, Opioid Withdrawal
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Quincy, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 16, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

Cognitive Enhancement in Bipolar Disorder

NCT00597896
View directory record Official record
Conditions
Bipolar Disorder
Interventions
pramipexole
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 16, 2026, 5:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease

NCT01968460
View directory record Official record
Conditions
Parkinson's Disease
Interventions
P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),, Placebo, P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),
Drug
Lead sponsor
Pharma Two B Ltd.
Industry
Eligibility
35 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 16, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

NCT00601523
View directory record Official record
Conditions
Parkinson Disease
Interventions
Placebo, Pramipexole
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Sun City, Arizona • Tempe, Arizona • La Jolla, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 16, 2026, 5:05 PM EDT
Terminated Phase 3 Interventional

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

NCT05763121
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Interventions
Dexpramipexole Dihydrochloride, Placebo
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
12 Years to 99 Years
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
89
States / cities
Bakersfield, California • La Palma, California • Newport Beach, California + 73 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 16, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional Results available

Pramipexole ER vs. Placebo in Fibromyalgia

NCT00689052
View directory record Official record
Conditions
Fibromyalgia
Interventions
pramipexole ER, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 16, 2026, 5:05 PM EDT
Recruiting Phase 2 Interventional

Stratified Pharmacological Approaches for Regulating Circuit-Level Effects

NCT07022405
View directory record Official record
Conditions
Depression - Major Depressive Disorder
Interventions
Pramipexole Immediate Release
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 16, 2026, 5:05 PM EDT
Suspended Phase 2 Interventional

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

NCT06705478
View directory record Official record
Conditions
Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
Interventions
Pramipexole ER, Escitalopram
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 16, 2026, 5:05 PM EDT
Completed Phase 4 Interventional Results available

Switching From Oral Dopamine Agonists to Rotigotine

NCT01976871
View directory record Official record
Conditions
Restless Legs Syndrome, Ekbom Syndrome, Willis-Ekbom Disease
Interventions
Rotigotine
Drug
Lead sponsor
John Winkelman, MD, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 16, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease

NCT01388478
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
R-pramipexole
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 16, 2026, 5:05 PM EDT
Enrolling by invitation Phase 4 Interventional

Quality Improvement and Practice Based Research in Neurology Using the EMR

NCT02670161
View directory record Official record
Conditions
Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
Interventions
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 100 Years
Enrollment
3,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 16, 2026, 5:05 PM EDT
Completed No phase listed Observational

Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study)

NCT00617019
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years to 75 Years
Enrollment
3,234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
36
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Sun City, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Oct 16, 2026, 5:05 PM EDT